Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

TP53 mutations occur in 15.7% of ALL and are associated with MYC -rearrangement, low hypodiploidy, and a poor prognosis

Anna Stengel, Susanne Schnittger, Sandra Weissmann, Sabrina Kuznia, Wolfgang Kern, Alexander Kohlmann, Torsten Haferlach, Claudia Haferlach

Blood (2014) 124 (2): 251–258.

https://doi.org/10.1182/blood-2014-02-558833

Published: 2014

Includes: Supplemental data

Journal Articles

RARS-T Patients Harbor SF3B1 Mutations In 90.2% and Can Be Characterized By Mutations In ASXL1 and Other Spliceosome Genes In Most Of The Remaining Cases

Sabine Jeromin, PhD, Christiane Eder, PhD, Sandra Weissmann, PhD, Manja Meggendorfer, PhD, Tamara Alpermann, Alexander Kohlmann, PhD, Wolfgang Kern, MD, Claudia Haferlach, MD, Torsten Haferlach, MD, Susanne Schnittger, PhD

Blood (2013) 122 (21): 2764.

https://doi.org/10.1182/blood.V122.21.2764.2764

Published: 2013

Journal Articles

Comparison Of Mutation Patterns Between Diagnosis and Relapse In 556 Adult Patients With AML Shows High Variability Of Stability

Susanne Schnittger, PhD, Niroshan Nadarajah, MSc, Tamara Alpermann, Christiane Eder, PhD, Alexander Kohlmann, PhD, Sabrina Kuznia, MSc, Sandra Weissmann, PhD, Annette Fasan, PhD, Simone Weber, Andreia Albuquerque, PhD, Sabine Jeromin, PhD, Manja Meggendorfer, PhD, Frank Dicker, PhD, Wolfgang Kern, MD, Claudia Haferlach, MD, Torsten Haferlach, MD

Blood (2013) 122 (21): 4978.

https://doi.org/10.1182/blood.V122.21.4978.4978

Published: 2013

Journal Articles

Diagnostic and Prognostic Utility Of a 26-Gene Panel For Deep-Sequencing Mutation Analysis In Myeloid Malignancies

Alexander Kohlmann, PhD, Sabrina Kuznia, MSc, Niroshan Nadarajah, MSc, Tamara Alpermann, Sandra Weissmann, PhD, Andreas Roller, PhD, Andreia Albuquerque, PhD, Wolfgang Kern, MD, Claudia Haferlach, MD, Susanne Schnittger, PhD, Torsten Haferlach, MD

Blood (2013) 122 (21): 1547.

https://doi.org/10.1182/blood.V122.21.1547.1547

Published: 2013

Journal Articles

IGHV Mutation Status Does Not Add Prognostic Information In The Background Of Mutations In TP53 and SF3B1, and Deletions Of 17p and 11q, Which Are Independent Adverse Prognostic Parameters In CLL

Claudia Haferlach, MD, Sabine Jeromin, PhD, Sandra Weissmann, PhD, Frank Dicker, PhD, Wolfgang Kern, MD, Susanne Schnittger, PhD, Alexander Kohlmann, PhD, Torsten Haferlach, MD

Blood (2013) 122 (21): 4110.

https://doi.org/10.1182/blood.V122.21.4110.4110

Published: 2013

Journal Articles

Risk Stratification In Chronic Lymphocytic Leukemia Patients With IGHV3-21 Gene Usage According To Presence Of Stereotypy and Mutations In SF3B1

Sabine Jeromin, PhD, Frank Dicker, PhD, Katharina Bayer, Sandra Weissmann, PhD, Christiane Eder, PhD, Manja Meggendorfer, PhD, Tamara Alpermann, Alexander Kohlmann, PhD, Torsten Haferlach, MD, Wolfgang Kern, MD, Claudia Haferlach, MD, Susanne Schnittger, PhD

Blood (2013) 122 (21): 4114.

https://doi.org/10.1182/blood.V122.21.4114.4114

Published: 2013

Journal Articles

Targeted Next-Generation Sequencing Of 2,761 Genes Detects Copy Number States and Molecular Mutations In a Single Approach

Alexander Kohlmann, PhD, Andreas Roller, PhD, Sandra Weissmann, PhD, Sabrina Kuznia, MSc, Melanie Zenger, Wolfgang Kern, MD, Susanne Schnittger, PhD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2013) 122 (21): 1371.

https://doi.org/10.1182/blood.V122.21.1371.1371

Published: 2013

Journal Articles

Tyrosine Kinase Inhibitor Treated CML Patients Harboring Philadelphia-Negative Cytogenetically Aberrant Clones Show Molecular Mutations In 31% Of Cases Not Present At Diagnosis: A High-Throughput Amplicon Sequencing Study Of 29 Genes

Susanne Schnittger, PhD, Sabrina Kuznia, MSc, Manja Meggendorfer, PhD, Niroshan Nadarajah, MSc, Sabine Jeromin, PhD, Tamara Alpermann, Andreas Roller, PhD, Andreia Albuquerque, PhD, Sandra Weissmann, PhD, Thomas Ernst, Christiane Eder, PhD, Frank Dicker, PhD, Wolfgang Kern, MD, Alexander Kohlmann, PhD, Torsten Haferlach, MD, Andreas Hochhaus, MD, Claudia Haferlach, MD

Blood (2013) 122 (21): 611.

https://doi.org/10.1182/blood.V122.21.611.611

Published: 2013

Journal Articles

Acute Lymphoblastic Leukemia (ALL) With Low-Hypodiploid/Near-Triploid Karyotype Is a Specific Clinical Entity Characterized By a High TP53 Mutation Frequency

Verena Patterer, PhD, Melanie Zenger, Susanne Schnittger, PhD, Sandra Weissmann, PhD, Franziska Poetzinger, Alexander Kohlmann, PhD, Frauke Bellos, MD, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2013) 122 (21): 615.

https://doi.org/10.1182/blood.V122.21.615.615

Published: 2013

Journal Articles

TP53 Mutations Are Present In 15.7% Of ALL, Are Especially Frequent In ALL With MYC -Rearrangement and In ALL With Low Hypodiploid Chromosome Status and Are Associated With Poor Prognosis

Claudia Haferlach, MD, Sandra Weissmann, PhD, Sabrina Kuznia, MSc, Susanne Schnittger, PhD, Wolfgang Kern, MD, Alexander Kohlmann, PhD, Torsten Haferlach, MD

Blood (2013) 122 (21): 827.

https://doi.org/10.1182/blood.V122.21.827.827

Published: 2013

Journal Articles

TP53 Alterations In CLL - Parameters Influencing The Prognostic Impact: A Study On 3,988 Patients

Claudia Haferlach, MD, Frank Dicker, PhD, Sabine Jeromin, PhD, Sandra Weissmann, PhD, Andreas Roller, PhD, Wenke Worseg, Tamara Alpermann, Wolfgang Kern, MD, Torsten Haferlach, MD, Alexander Kohlmann, PhD, Susanne Schnittger, PhD

Blood (2013) 122 (21): 865.

https://doi.org/10.1182/blood.V122.21.865.865

Published: 2013

Journal Articles

A 13-Gene Panel Targeted To Investigate CLL By Next-Generation Amplicon Deep-Sequencing Can Be Successfully Implemented In Routine Diagnostics

Alexander Kohlmann, PhD, Andreas Roller, PhD, Andreia Albuquerque, PhD, Sabrina Kuznia, MSc, Sandra Weissmann, PhD, Sabine Jeromin, PhD, Wolfgang Kern, MD, Claudia Haferlach, MD, Susanne Schnittger, PhD, Torsten Haferlach, MD

Blood (2013) 122 (21): 867.

https://doi.org/10.1182/blood.V122.21.867.867

Published: 2013

Journal Articles

Acquisition of TP53 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients During the Course of Disease Is Associated with an Unmutated IGHV Status and Mutations in XPO1 and SF3B1

Vera Grossmann, MSc, Alexander Kohlmann, PhD, Susanne Schnittger, PhD, Sandra Weissmann, PhD, Frank Dicker, PhD, Sabine Jeromin, PhD, Lucia Boeck, Tamara Alpermann, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2012) 120 (21): 1768.

https://doi.org/10.1182/blood.V120.21.1768.1768

Published: 2012

Journal Articles

Clinical Relevance of Concomitant Gene Mutations in CEBPA Double-Mutated Acute Myeloid Leukemia.

Vera Grossmann, MSc, Susanne Schnittger, PhD, Niroshan Nadarajah, MSc, Sandra Weissmann, PhD, Annette Fasan, PhD, Christiane Eder, PhD, Elisa Stopp, Wolfgang Kern, MD, Torsten Haferlach, MD, Alexander Kohlmann, PhD, Claudia Haferlach, MD

Blood (2012) 120 (21): 2400.

https://doi.org/10.1182/blood.V120.21.2400.2400

Published: 2012

Journal Articles

Prognostic Impact of NOTCH1 Mutations in Chronic Lymphocytic Leukemia (CLL): A Study On 538 Patients.

Sandra Weissmann, PhD, Andreas Roller, PhD, Vera Grossmann, MSc, Claudia Haferlach, MD, Wolfgang Kern, MD, Torsten Haferlach, MD, Susanne Schnittger, PhD, Alexander Kohlmann, PhD

Blood (2012) 120 (21): 2873.

https://doi.org/10.1182/blood.V120.21.2873.2873

Published: 2012

Journal Articles

Recurrent ATM and BIRC3 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) and Deletion 11q22-q23

Vera Grossmann, MSc, Alexander Kohlmann, PhD, Susanne Schnittger, PhD, Sandra Weissmann, PhD, Sabine Jeromin, PhD, Jennifer Kienast, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2012) 120 (21): 1771.

https://doi.org/10.1182/blood.V120.21.1771.1771

Published: 2012

Journal Articles

Acute Erythroid Leukemia (AEL) Can Be Separated Into Distinct Prognostic Subsets Based On Cytogenetic and Molecular Genetic Characteristics

Vera Grossmann, MSc, Claudia Haferlach, MD, Susanne Schnittger, PhD, Ulrike Bacher, MD, Franziska Poetzinger, Sandra Weissmann, PhD, Andreas Roller, PhD, Christiane Eder, PhD, Annette Fasan, PhD, Melanie Zenger, Marita Staller, Wolfgang Kern, MD, Alexander Kohlmann, PhD, Torsten Haferlach, MD

Blood (2012) 120 (21): 1394.

https://doi.org/10.1182/blood.V120.21.1394.1394

Published: 2012

Journal Articles

SF3B1 Mutations Have Adverse Impact On Time to Treatment Especially in Patients with 13q Deletions: A Study On 1,124 Chronic Lymphocytic Leukemia (CLL) Patients

Sabine Jeromin, PhD, Claudia Haferlach, MD, Katharina Bayer, Frank Dicker, PhD, Sandra Weissmann, PhD, Vera Grossmann, MSc, Tamara Alpermann, Alexander Kohlmann, PhD, Torsten Haferlach, MD, Wolfgang Kern, MD, Susanne Schnittger, PhD

Blood (2012) 120 (21): 709.

https://doi.org/10.1182/blood.V120.21.709.709

Published: 2012

Journal Articles

Mixed Phenotype Acute Leukemia, T/Myeloid, NOS (MPAL-TM) Has a High DNMT3A Mutation Frequency and Carries Further Genetic Features of Both AML and T-ALL: Results of a Comprehensive Next-Generation Sequencing Study Analyzing 32 Genes

Wolfgang Kern, MD, Vera Grossmann, MSc, Andreas Roller, PhD, Sandra Weissmann, PhD, Tamara Alpermann, Ulrike Schoeck, MSc, Claudia Haferlach, MD, Susanne Schnittger, PhD, Torsten Haferlach, MD, Alexander Kohlmann, PhD

Blood (2012) 120 (21): 403.

https://doi.org/10.1182/blood.V120.21.403.403

Published: 2012

Journal Articles

First Results of a 31-Gene Panel Targeted to Investigate Myeloid Malignancies by Next-Generation Amplicon Deep-Sequencing

Alexander Kohlmann, PhD, Sandra Weissmann, PhD, Ulrike Schoeck, MSc, Vera Grossmann, MSc, Wolfgang Kern, MD, Claudia Haferlach, MD, Susanne Schnittger, PhD, Torsten Haferlach, MD

Blood (2012) 120 (21): 883.

https://doi.org/10.1182/blood.V120.21.883.883

Published: 2012

NARROW

TP53 mutations occur in 15.7% of ALL and are associated with MYC -rearrangement, low hypodiploidy, and a poor prognosis

RARS-T Patients Harbor SF3B1 Mutations In 90.2% and Can Be Characterized By Mutations In ASXL1 and Other Spliceosome Genes In Most Of The Remaining Cases

Comparison Of Mutation Patterns Between Diagnosis and Relapse In 556 Adult Patients With AML Shows High Variability Of Stability

Diagnostic and Prognostic Utility Of a 26-Gene Panel For Deep-Sequencing Mutation Analysis In Myeloid Malignancies

IGHV Mutation Status Does Not Add Prognostic Information In The Background Of Mutations In TP53 and SF3B1, and Deletions Of 17p and 11q, Which Are Independent Adverse Prognostic Parameters In CLL

Risk Stratification In Chronic Lymphocytic Leukemia Patients With IGHV3-21 Gene Usage According To Presence Of Stereotypy and Mutations In SF3B1

Targeted Next-Generation Sequencing Of 2,761 Genes Detects Copy Number States and Molecular Mutations In a Single Approach

Tyrosine Kinase Inhibitor Treated CML Patients Harboring Philadelphia-Negative Cytogenetically Aberrant Clones Show Molecular Mutations In 31% Of Cases Not Present At Diagnosis: A High-Throughput Amplicon Sequencing Study Of 29 Genes

Acute Lymphoblastic Leukemia (ALL) With Low-Hypodiploid/Near-Triploid Karyotype Is a Specific Clinical Entity Characterized By a High TP53 Mutation Frequency

TP53 Mutations Are Present In 15.7% Of ALL, Are Especially Frequent In ALL With MYC -Rearrangement and In ALL With Low Hypodiploid Chromosome Status and Are Associated With Poor Prognosis

TP53 Alterations In CLL - Parameters Influencing The Prognostic Impact: A Study On 3,988 Patients

A 13-Gene Panel Targeted To Investigate CLL By Next-Generation Amplicon Deep-Sequencing Can Be Successfully Implemented In Routine Diagnostics

Acquisition of TP53 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients During the Course of Disease Is Associated with an Unmutated IGHV Status and Mutations in XPO1 and SF3B1

Clinical Relevance of Concomitant Gene Mutations in CEBPA Double-Mutated Acute Myeloid Leukemia.

Prognostic Impact of NOTCH1 Mutations in Chronic Lymphocytic Leukemia (CLL): A Study On 538 Patients.

Recurrent ATM and BIRC3 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) and Deletion 11q22-q23

Acute Erythroid Leukemia (AEL) Can Be Separated Into Distinct Prognostic Subsets Based On Cytogenetic and Molecular Genetic Characteristics

SF3B1 Mutations Have Adverse Impact On Time to Treatment Especially in Patients with 13q Deletions: A Study On 1,124 Chronic Lymphocytic Leukemia (CLL) Patients

Mixed Phenotype Acute Leukemia, T/Myeloid, NOS (MPAL-TM) Has a High DNMT3A Mutation Frequency and Carries Further Genetic Features of Both AML and T-ALL: Results of a Comprehensive Next-Generation Sequencing Study Analyzing 32 Genes

First Results of a 31-Gene Panel Targeted to Investigate Myeloid Malignancies by Next-Generation Amplicon Deep-Sequencing

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only